Clinical Study
A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis
Table 4
Adverse events during the treatments.
| | Adverse events (AEs) | Number of the patients | Serious AEs resulting in drug withdrawal |
| | Infliximab group () | | Infusion reaction | 1 | 1 | | Delayed hypersensitivity reaction | 1 | 1 | | Leukocytopenia | 1 | 1 | | Anemia | 2 | 0 | | Pneumonia | 2 | 2 | | Idiopathic thrombocytopenic purpura | 1 | 1 | | Total | 8 | 6 (12.5%) |
| | Tacrolimus group () | | Renal dysfunction | 8 | 1 | | Hot flushes | 4 | 0 | | Tremor | 4 | 0 | | Headache | 5 | 0 | | Hypomagnesemia | 5 | 0 | | Liver dysfunction | 1 | 1 | | Total | 27 | 2 (4.3%) |
|
|
